Literature DB >> 23199894

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study.

Carlos Besses1, Jean-Jacques Kiladjian, Martin Griesshammer, Luigi Gugliotta, Claire Harrison, Ruth Coll, Jonathan Smith, Brihad Abhyankar, Gunnar Birgegård.   

Abstract

EXELS is an ongoing phase IV non-interventional study; 3643 high-risk patients with essential thrombocythemia (ET) were recruited across 13 European countries. We report patient characteristics and cytoreductive treatment patterns of ET across Europe. Hydroxycarbamide (HC; 64.3%) and anagrelide (22.0%) were the two main cytoreductive treatments prescribed. The proportions of patients taking either HC or anagrelide varied across countries, as did the number of patients receiving anti-aggregatory therapy in addition to cytoreductive treatment. This real-world evidence demonstrates that, generally, treatment patterns of ET across Europe adhere to expert recommendations, with some notable variations between countries.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23199894     DOI： 10.1016/j.leukres.2012.11.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  6 in total

1.  Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia.

Authors:  Yuzuru Kanakura; Yoshitaka Miyakawa; Paul Wilde; Jonathan Smith; Heinrich Achenbach; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2014-08-27       Impact factor: 2.490

2.  Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Authors:  Luigi Gugliotta; Carlos Besses; Martin Griesshammer; Claire Harrison; Jean-Jacques Kiladjian; Ruth Coll; Jonathan Smith; Brihad Abhyankar; Gunnar Birgegård
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

3.  A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.

Authors:  Yuzuru Kanakura; Yukari Shirasugi; Hiroki Yamaguchi; Michiaki Koike; Takaaki Chou; Shinichiro Okamoto; Heinrich Achenbach; Jingyang Wu; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2018-08-18       Impact factor: 2.490

4.  Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.

Authors:  Jérôme Rey; Jean-François Viallard; Karim Keddad; Jonathan Smith; Paul Wilde; Jean-Jacques Kiladjian
Journal:  Eur J Haematol       Date:  2013-11-25       Impact factor: 2.997

Review 5.  The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

6.  Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Authors:  Tomoki Ito; Yoshinori Hashimoto; Yasuhiro Tanaka; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Akiko Hashimoto; Toshinori Kondo; Hiromi Omura; Isaku Shinzato; Takayuki Tanaka; Shosaku Nomura
Journal:  Eur J Haematol       Date:  2019-06-17       Impact factor: 2.997
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.